ARTICLE | Emerging Company Profile
Marengo taps T cell stimulation white space with $80M from ATP
The company’s antibodies against germline-encoded regions of the TCR show promise as single agents for cancer
November 10, 2021 2:25 AM UTC
ATP-built Marengo is advancing an underexplored area of T cell biology via antibody fusion proteins that activate long-lasting, polyclonal responses against solid tumors.
“We’re tapping into brand-new biology that’s not fully described in textbooks,” said Marengo Therapeutics Inc. CEO Zhen Su, who was formerly SVP and head of global oncology at Merck KGaA (Xetra:MRK)...